|
| 36097168 | Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy. | Prostate Cancer Prostatic Dis | 2024 |
| 37085425 | Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. | Eur Urol | 2024 |
| 36872133 | Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. | Eur Urol | 2023 |
| 37596191 | Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. | Eur Urol | 2023 |
| 37526936 | Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. | JAMA Netw Open | 2023 |
| 37524096 | Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. | Lancet | 2023 |
| 37961155 | Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction. | medRxiv | 2023 |
| 37945903 | Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. | Nat Genet | 2023 |
| 37326322 | Cardiovascular Safety of Testosterone-Replacement Therapy. | N Engl J Med | 2023 |
| 37351909 | Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. | Cancer Epidemiol Biomarkers Prev | 2023 |
| 37087309 | Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. | Eur Urol Oncol | 2023 |
| 37285550 | Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic. | JCO Oncol Pract | 2023 |
| 37414705 | Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). | Eur Urol | 2023 |
| 37343766 | Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study. | Mod Pathol | 2023 |
| 37335291 | Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer. | Oncotarget | 2023 |
| 37264206 | Genetically adjusted PSA levels for prostate cancer screening. | Nat Med | 2023 |
| 37096582 | Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. | J Urol | 2023 |
| 37096575 | Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. | J Urol | 2023 |
| 36402643 | Impact of Finasteride on Survival in Bladder Cancer: A Retrospective Multi-institutional Database Analysis. | Clin Genitourin Cancer | 2023 |
| 34127801 | Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. | Prostate Cancer Prostatic Dis | 2022 |
| 35351104 | Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials. | BMC Urol | 2022 |
| 35343252 | Absolute Prostate Specific Antigen after 6 Months of Androgen Deprivation Therapy Is a Predictor of Overall and Cancer-Specific Mortality in Men with Hormone-Sensitive Prostate Cancer. | J Urol | 2022 |
| 35467778 | Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. | Cancer Med | 2022 |
| 35446628 | Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). | J Clin Oncol | 2022 |
| 36084322 | Differential Biopsy Patterns Influence Associations between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 33511883 | Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. | Nutr Cancer | 2022 |
| 34920976 | Advancing Traditional Prostate-specific Antigen Kinetics in the Detection of Prostate Cancer: A Machine Learning Model. | Eur Urol Focus | 2022 |
| 34889205 | Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. | Endocr Relat Cancer | 2022 |
| 35096612 | Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. | Front Oncol | 2022 |
| 35150214 | Legends in Urology V29I01. | Can J Urol | 2022 |
| 35176252 | Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. | Hum Pathol | 2022 |
| 35145197 | Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25â¿¿mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma. | Mod Pathol | 2022 |
| 35031163 | A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. | Eur Urol | 2022 |
| 35260348 | Hereditary Cancer Gene Variants in Hispanic Men With a Personal or Family History of Prostate Cancer. | Clin Genitourin Cancer | 2022 |
| 34815548 | Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial. | Prostate Cancer Prostatic Dis | 2022 |
| 34516660 | Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. | Cancer | 2022 |
| 32701201 | Age-related macular degeneration in a randomized trial of selenium and vitamin E in men: the Select Eye Endpoints (SEE) study (SWOG S0000B). | Acta Ophthalmol | 2021 |
| 33574088 | Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. | Cancer Res | 2021 |
| 33514567 | Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression. | Cancer Prev Res (Phila) | 2021 |
| 33568346 | A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). | Clin Cancer Res | 2021 |
| 33592176 | A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. | Lancet | 2021 |
| 33500355 | Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). | Clin Cancer Res | 2021 |
| 34045187 | Contacts with Macrophages Promote an Aggressive Nanomechanical Phenotype of Circulating Tumor Cells in Prostate Cancer. | Cancer Res | 2021 |
| 34258619 | Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. | Am J Clin Nutr | 2021 |
| 33398198 | Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. | Nat Genet | 2021 |
| 33473200 | Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. | Nat Genet | 2021 |
| 32739353 | A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancer. | J Geriatr Oncol | 2021 |
| 32930425 | African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. | Int J Cancer | 2021 |
| 31226226 | A genome-wide association study of prostate cancer in Latinos. | Int J Cancer | 2020 |
| 32055002 | Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. | Prostate Cancer Prostatic Dis | 2020 |